Velocity Gradient Separation Reveals a New Extracellular Vesicle Population Enriched in miR-155 and Mitochondrial DNA.

HIV biomarker calprotectin extracellular vesicles miR-155 miR-223 miR-92 mtDNA velocity gradient virions

Journal

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317

Informations de publication

Date de publication:
27 Apr 2021
Historique:
received: 04 03 2021
revised: 10 04 2021
accepted: 20 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Extracellular vesicles (EVs) and their contents (proteins, lipids, messenger RNA, microRNA, and DNA) are viewed as intercellular signals, cell-transforming agents, and shelters for viruses that allow both diagnostic and therapeutic interventions. EVs circulating in the blood of individuals infected with human immunodeficiency virus (HIV-1) may provide insights into pathogenesis, inflammation, and disease progression. However, distinguishing plasma membrane EVs from exosomes, exomeres, apoptotic bodies, virions, and contaminating proteins remains challenging. We aimed at comparing sucrose and iodixanol density and velocity gradients along with commercial kits as a means of separating EVs from HIV particles and contaminating protein like calprotectin; and thereby evaluating the suitability of current plasma EVs analysis techniques for identifying new biomarkers of HIV-1 immune activation. Multiple analysis have been performed on HIV-1 infected cell lines, plasma from HIV-1 patients, or plasma from HIV-negative individuals spiked with HIV-1. Commercial kits, the differential centrifugation and density or velocity gradients to precipitate and separate HIV, EVs, and proteins such as calprotectin, have been used. EVs, virions, and contaminating proteins were characterized using Western blot, ELISA, RT-PCR, hydrodynamic size measurement, and enzymatic assay. Conversely to iodixanol density or velocity gradient, protein and virions co-sedimented in the same fractions of the sucrose density gradient than AChE-positive EVs. Iodixanol velocity gradient provided the optimal separation of EVs from viruses and free proteins in culture supernatants and plasma samples from a person living with HIV (PLWH) or a control and revealed a new population of large EVs enriched in microRNA miR-155 and mitochondrial DNA. Although EVs and their contents provide helpful information about several key events in HIV-1 pathogenesis, their purification and extensive characterization by velocity gradient must be investigated thoroughly before further use as biomarkers. By revealing a new population of EVs enriched in miR-155 and mitochondrial DNA, this study paves a way to increase our understanding of HIV-1 pathogenesis.

Identifiants

pubmed: 33925397
pii: pathogens10050526
doi: 10.3390/pathogens10050526
pmc: PMC8146806
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Virol. 1997 Mar;71(3):1922-30
pubmed: 9032323
Traffic. 2010 Jan;11(1):110-22
pubmed: 19912576
Cell Rep. 2019 Apr 16;27(3):940-954.e6
pubmed: 30956133
Front Microbiol. 2018 Oct 10;9:2411
pubmed: 30364166
Methods. 2012 Feb;56(2):293-304
pubmed: 22285593
J Immunol Methods. 2008 Sep 30;338(1-2):21-30
pubmed: 18675270
J Immunol Methods. 2014 Sep;411:55-65
pubmed: 24952243
J Virol. 2014 Oct;88(19):11529-39
pubmed: 25056899
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317276
Cell Microbiol. 2013 Mar;15(3):412-29
pubmed: 23072732
J Immunol Methods. 2002 Dec 20;271(1-2):185-201
pubmed: 12445741
Methods. 2015 Oct 1;87:46-58
pubmed: 26044649
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Exp Neurol. 2015 Mar;265:84-93
pubmed: 25562527
FASEB J. 2014 Aug;28(8):3703-19
pubmed: 24812088
Nat Med. 2007 Oct;13(10):1241-7
pubmed: 17906637
J Biol Chem. 1987 Jul 5;262(19):9412-20
pubmed: 3597417
J Biol Chem. 2013 Jul 5;288(27):20014-33
pubmed: 23661700
J Extracell Vesicles. 2017 Jun 20;6(1):1329476
pubmed: 28717422
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
Prostate. 2019 Nov;79(15):1767-1776
pubmed: 31475741
J Virol. 2002 Feb;76(3):1004-14
pubmed: 11773376
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
J Cell Biol. 1968 Jan;36(1):103-9
pubmed: 19806697
Nucleic Acids Res. 2012 Mar;40(5):2181-96
pubmed: 22080513
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Retrovirology. 2014 Jun 12;11:46
pubmed: 24924541
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9155-61
pubmed: 27432966
Blood. 2011 Jun 16;117(24):6589-99
pubmed: 21536857
J Chromatogr A. 2019 Mar 15;1588:77-84
pubmed: 30616980
J Extracell Vesicles. 2012 Apr 16;1:
pubmed: 24009879
Blood. 2012 Jun 28;119(26):6259-67
pubmed: 22286198
AIDS. 1999 Feb 4;13(2):281-3
pubmed: 10202836
J Cell Biol. 1983 Aug;97(2):329-39
pubmed: 6309857
Pathog Immun. 2021 Jan 14;6(1):1-28
pubmed: 33987483
J Transl Med. 2018 Jan 9;16(1):1
pubmed: 29316942
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
J Virol. 1999 Feb;73(2):1460-7
pubmed: 9882352
J Vis Exp. 2016 Jan 05;(107):
pubmed: 26780239
J Leukoc Biol. 2004 Aug;76(2):433-40
pubmed: 15107458
Sci Rep. 2016 Aug 09;6:31175
pubmed: 27503761
Virology. 2015 Oct;484:103-112
pubmed: 26092249
J Infect Dis. 2015 Jun 1;211(11):1712-6
pubmed: 25512626
PLoS One. 2015 Dec 21;10(12):e0145686
pubmed: 26690353
Can J Physiol Pharmacol. 2015 Oct;93(10):855-61
pubmed: 26030833
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):219-27
pubmed: 26181817
Curr Pharm Des. 2017;23(28):4098-4102
pubmed: 28677507
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Adv Exp Med Biol. 2015;887:31-51
pubmed: 26662985
Adv Virol. 2016;2016:9852494
pubmed: 26981123
Arthritis Rheum. 2006 Dec;54(12):3809-14
pubmed: 17133577
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
AIDS Res Hum Retroviruses. 2011 Feb;27(2):167-78
pubmed: 20964480
J Immunol Res. 2015;2015:296149
pubmed: 27057553
Kidney Int. 2012 Nov;82(9):1024-32
pubmed: 22785172
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179
J Extracell Vesicles. 2018 Jun 26;7(1):1490145
pubmed: 29963299
Nature. 1971 Jul 30;232(5309):340-1
pubmed: 5094840
J Biol Chem. 2016 Jan 15;291(3):1251-66
pubmed: 26553869
Immunology. 2015 Jul;145(3):323-33
pubmed: 25829072
Traffic. 2011 Dec;12(12):1659-68
pubmed: 21645191
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422

Auteurs

Myriam Vaillancourt (M)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Audrey Hubert (A)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Caroline Subra (C)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.

Julien Boucher (J)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Wilfried Wenceslas Bazié (WW)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Programme de Recherche sur les Maladies Infectieuses, Centre Muraz, Institut National de Santé Publique, Bobo-Dioulasso 01 BP 390, Burkina Faso.

Julien Vitry (J)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Sofiane Berrazouane (S)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Jean-Pierre Routy (JP)

Chronic Viral Illness Service and Division of Hematology, McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
Infectious Diseases and Immunity in Global Health Program, Research Institute, McGill University Health Centre, Montréal, QC H4A 3J1, Canada.

Sylvie Trottier (S)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Centre de Recherche du CHU de Québec, Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Cécile Tremblay (C)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC H3C 3J7, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada.

Mohammad-Ali Jenabian (MA)

Département des Sciences Biologiques et Centre de Recherche CERMO-FC, Université du Québec à Montréal (UQAM), Montréal, QC H2L 2C4, Canada.

Abderrahim Benmoussa (A)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Department of Nutrition, CHU Sainte-Justine-Université de Montréal, Montréal, QC H3T 1J4, Canada.

Patrick Provost (P)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Centre de Recherche du CHU de Québec, Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Philippe A Tessier (PA)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Centre de Recherche du CHU de Québec, Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Caroline Gilbert (C)

Centre de Recherche du CHU de Québec-Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.
Centre de Recherche du CHU de Québec, Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université Laval, T1-49, 2705 boulevard Laurier, Québec, QC G1V 4G2, Canada.

Classifications MeSH